PubRank

W C Eckelman

Author PubWeight™ 86.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997 3.00
2 PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003 1.86
3 Clinical evaluation of radiolabeled bleomycin (BLEO) for tumor detection. J Nucl Med 1974 1.60
4 A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009 1.60
5 Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997 1.55
6 A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 2001 1.49
7 The suitability of [11C]-alpha-methyl-L-tryptophan as a tracer for serotonin synthesis: studies with dual administration of [11C] and [14C] labeled tracer. J Cereb Blood Flow Metab 2000 1.48
8 Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999 1.31
9 Evaluation of 99m Tc-DTPA for the measurement of glomerular filtration rate. J Nucl Med 1972 1.30
10 Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab 1997 1.28
11 Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem 1999 1.27
12 PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl Med Biol 2000 1.20
13 Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med 2000 1.20
14 Radioassays and experimental evaluation of dose calibrator settings for 18F. Appl Radiat Isot 2001 1.15
15 Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography. JAMA 1985 1.04
16 Cellular release of [18F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 2000 1.02
17 Brain incorporation of [1-11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. Brain Res 1997 1.00
18 High resolution PET, SPECT and projection imaging in small animals. Comput Med Imaging Graph 2001 0.99
19 The labeling of high affinity sites of antibodies with 99mTc. Int J Nucl Med Biol 1985 0.98
20 Pharmacokinetic analysis of blood distribution of intravenously administered 153Gd-labeled Gd(DTPA)2- and 99mTc(DTPA) in rats. Magn Reson Imaging 1990 0.97
21 L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res 1996 0.97
22 Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nucl Med Biol 2004 0.96
23 Extra-osseous localization of 99Tcm-Sn pyrophosphate. Br J Radiol 1975 0.96
24 Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000 0.96
25 Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 2001 0.95
26 One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl Radiat Isot 1994 0.95
27 Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. Nucl Med Biol 2000 0.93
28 Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. Nucl Med Biol 2001 0.93
29 Radiolabeling of antibodies. Cancer Res 1980 0.93
30 Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At. Radiat Res 2002 0.91
31 Targeting of transferrin receptors in nude mice bearing A431 and LS174T xenografts with [18F]holo-transferrin: permeability and receptor dependence. J Nucl Med 1999 0.90
32 Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab 1998 0.89
33 Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry 2010 0.87
34 Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. Nucl Med Biol 1998 0.87
35 Splenic sequestration of 99m Tc-labeled red blood cells. J Nucl Med 1972 0.86
36 Receptor-binding radiotracers: a class of potential radiopharmaceuticals. J Nucl Med 1979 0.86
37 Biologically stable [(18)F]-labeled benzylfluoride derivatives. Nucl Med Biol 2000 0.86
38 Labeling proteins at high specific activity using N-succinimidyl 4-[18F](fluoromethyl) benzoate. Appl Radiat Isot 1997 0.86
39 Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology 2003 0.85
40 Radiosynthesis of [18F]3-acetylcyclofoxy: a high affinity opiate antagonist. Int J Appl Radiat Isot 1985 0.84
41 Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. J Cereb Blood Flow Metab 2000 0.83
42 Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment. Bioconjug Chem 1997 0.83
43 A neutral technetium-99m complex for myocardial imaging. J Nucl Med 1989 0.83
44 Role of radionuclide imaging in trials of antiangiogenic therapy. Acad Radiol 2000 0.82
45 The single-pass cerebral extraction and capillary permeability-surface area product of several putative cerebral blood flow imaging agents. J Nucl Med 1993 0.82
46 Estrogen derivatives for the external localization of estrogen-dependent malignancy. J Nucl Med 1977 0.82
47 Analysis of residual solvents in 2-[(18)F]FDG by GC. Nucl Med Biol 2001 0.82
48 Positron-labeled angiotensin-converting enzyme (ACE) inhibitor: fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography. J Nucl Med 1991 0.82
49 Incorporation of [1-carbon-11]palmitate in monkey brain using PET. J Nucl Med 1995 0.82
50 Differences in affinities of muscarinic acetylcholine receptor antagonists for brain and heart receptors. Biochem Pharmacol 1983 0.81
51 Evaluation of human transferrin radiolabeled with N-succinimidyl 4-[fluorine-18](fluoromethyl) benzoate. J Nucl Med 1996 0.81
52 Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 1988 0.81
53 Molecular Imaging and Contrast Agent Database (MICAD): evolution and progress. Mol Imaging Biol 2012 0.81
54 Relative reactivity of DTPA, immunoreactive antibody-DTPA conjugates, and nonimmunoreactive antibody-DTPA conjugates toward indium-111. J Nucl Med 1985 0.81
55 The gallium-deferoxamine complex: stability with different deferoxamine concentrations and incubation conditions. Appl Radiat Isot 1998 0.81
56 A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. Ther Drug Monit 1990 0.80
57 Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride. J Nucl Med 1983 0.80
58 Why does the agonist [(18)F]FP-TZTP bind preferentially to the M(2) muscarinic receptor? Eur J Nucl Med Mol Imaging 2005 0.80
59 Liquid chromatography-tandem mass spectrometry identification of metabolites of two 5-HT1A antagonists, N-[2-[4-(2-methoxylphenyl)piperazino]ethyl]-N-(2-pyridyl) trans- and cis-4-fluorocyclohexanecarboxamide, produced by human and rat hepatocytes. J Chromatogr B Biomed Sci Appl 2001 0.80
60 Transchelation of 99mTc from low affinity sites to high affinity sites of antibody. Int J Rad Appl Instrum B 1986 0.80
61 3-[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals. FEBS Lett 1984 0.80
62 Syntheses and D2 receptor affinities of derivatives of spiperone containing aliphatic halogens. Int J Rad Appl Instrum A 1986 0.80
63 Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor. Bioorg Med Chem Lett 2000 0.79
64 Distribution of labeled bleomycin in normal and tumor-bearing mice. J Nucl Med 1973 0.79
65 Preparation of 18F-labeled muscarinic agonist with M2 selectivity. J Med Chem 1995 0.79
66 Comparison of 99mTc and 111In labeling of conjugated antibodies. Int J Rad Appl Instrum B 1986 0.79
67 In vivo chemistry of 99mTc-chelates. Int J Appl Radiat Isot 1982 0.79
68 Cobalt-labeled bleomycin--a new radiopharmaceutical for tumor localization. A comparative clinical evaluation with gallium citrate. J Nucl Med 1975 0.79
69 A multi-organ, axially distributed model of capillary permeability for a magnetic resonance imaging contrast agent. J Pharm Sci 1993 0.79
70 Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: the pharmacokinetics of two PET-labeled low molecular weight proteins. Q J Nucl Med 1997 0.78
71 Labeling monoclonal antibodies and F(ab')2 fragments with (111In) indium using cyclic DTPA anhydride and their in vivo behavior in mice bearing human tumor xenografts. Cancer Drug Deliv 1984 0.78
72 The characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro. J Nucl Med 1984 0.78
73 Optimization of the DTPA mixed-anhydride reaction with antibodies at low concentration. J Nucl Med 1983 0.78
74 99m Tc-human serum albumin. J Nucl Med 1971 0.78
75 Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols. J Med Chem 1979 0.78
76 A neutral lipophilic technetium-99m complex for regional cerebral blood flow imaging. J Nucl Med 1990 0.78
77 External imaging of cerebral muscarinic acetylcholine receptors. Science 1984 0.78
78 The classification of radiotracers. J Nucl Med 1978 0.78
79 The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type. Bioorg Med Chem Lett 2001 0.77
80 Measurement of transferrin receptor kinetics in the baboon liver using dynamic positron emission tomography imaging and [18F]holo-transferrin. Hepatology 1997 0.77
81 The distribution of the muscarinic acetylcholine receptor antagonists, quinuclidinyl benzilate and quinuclidinyl benzilate methiodide (both tritiated), in rat, guinea pig, and rabbit. J Nucl Med 1979 0.77
82 In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazolyl tetrahydropyridines. Synapse 1999 0.77
83 (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors. Peptides 1998 0.77
84 Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Life Sci 1999 0.77
85 Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv. Cancer Res 1998 0.76
86 Technetium labeling of monoclonal antibodies with functionalized BATOs: 2. TcCl(DMG)3CPITC labeling of B72.3 and NP-4 whole antibodies and NP-4 F(ab')2. Bioconjug Chem 1992 0.76
87 Monitoring the correction of glycogen storage disease type 1a in a mouse model using [(18)F]FDG and a dedicated animal scanner. Life Sci 2002 0.76
88 A rapid simple improved method for the preparation of Tc99m red blood cells for the determination of red cell volume. Am J Roentgenol Radium Ther Nucl Med 1973 0.76
89 In vivo functional imaging using receptor-binding radiopharmaceuticals. Technetium 99m-galactosyl-neoglycoalbumin as a model. Invest Radiol 1993 0.75
90 Technetium labeling of monoclonal antibodies with functionalized BATOs. 1. TcCl(DMG)3PITC. Bioconjug Chem 1991 0.75
91 The toxicity of Sn-pyrophosphate: clinical manifestations prior to acute LD50. J Nucl Med 1974 0.75
92 VIP and breast cancer. Ann N Y Acad Sci 1998 0.75
93 Tc-99m labeled red blod cells: a new radiopharmaceutical for the determination of total blood volume and blood pool scanning. Med Ann Dist Columbia 1973 0.75
94 Synthesis and screening of conformationally restricted and conformationally free N-(tertiary aminoalkyl)dithiocarbamic acids and esters as inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem 1998 0.75
95 Receptor-selective localization in pancreas. Int J Nucl Med Biol 1985 0.75
96 Biological distribution of chemical analogs of fatty acids and long chain hydrocarbons containing a strong chelating agent. J Pharm Sci 1977 0.75
97 Three radioligands compared for determining cytoplasmic estrogen-receptor content of human breast carcinomas. Clin Chem 1982 0.75
98 [I-125] 17 alpha-Iodovinyl 11 beta-methoxyestradiol: in vivo and in vitro properties of a high-affinity estrogen-receptor radiopharmaceutical. J Nucl Med 1984 0.75
99 Evaluation of stereoisomers of 4-fluoroalkyl analogues of 3-quinuclidinyl benzilate in in vivo competition studies for the M1, M2, and M3 muscarinic receptor subtypes in brain. Nucl Med Biol 1995 0.75
100 Instant 99m compounds. Nucl Med (Stuttg) 1971 0.75
101 Receptors labeled with gamma-emitting radiotracers. Int J Rad Appl Instrum B 1986 0.75
102 Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment. J Nucl Med 1997 0.75
103 Technetium-99m-pyridoxylideneglutamate, a new agent for gallbladder imaging: comparison with 131I-rose bengal. J Nucl Med 1976 0.75
104 In vivo receptor binding of iodinated beta-adrenoceptor blockers. J Nucl Med 1980 0.75
105 High-specific-activity 99m Tc Human serum albumin. Radiology 1972 0.75
106 [125I] 3-quinuclidinyl 4-iodobenzilate: a high affinity, high specific activity radioligand for the M1 and M2-acetylcholine receptors. Life Sci 1984 0.75
107 The chemical state of 99m Tc in biomedical products. II. The chelation of reduced technetium with DTPA. J Nucl Med 1972 0.75
108 Syntheses and biological properties of chiral fluoroalkyl quinuclidinyl benzilates. J Med Chem 1995 0.75
109 Iodinated bleomycin: an unsatisfactory radiopharmaceutical for tumor localization. J Nucl Med 1976 0.75
110 Reversed-phase high-performance liquid chromatography of bleomycin. J Chromatogr 1976 0.75
111 One of three thousand. J Nucl Med 1981 0.75
112 The feasibility of recycling glass liquid scintillation vials. Health Phys 1982 0.75
113 Analogues of 3-quinuclidinyl benzilate. J Med Chem 1982 0.75
114 Radiopharmaceuticals labelled with technetium. Int J Appl Radiat Isot 1977 0.75
115 Evaluation of 99mTc-DTPA prepared by three different methods. Radiology 1971 0.75
116 In vivo and in vitro characteristics of the N-methyl derivative of [125I]3-quinuclidinyl 4-iodobenzilate. Int J Nucl Med Biol 1984 0.75
117 Decreased tumor uptake of gallium-67 in animals after whole-body irradiation. J Nucl Med 1978 0.75
118 [77Br]-17-alpha-Bromoethynylestradiol: in vivo and in vitro characterization of an estrogen receptor radiotracer. Int J Nucl Med Biol 1982 0.75
119 Synthesis and evaluation of (17 alpha,20E)-21-[125I]iodo-19-norpregna-1,3,5(10),20-tetraene-3,17 -diol and (17 alpha,20E)-21-[125I]iodo-11 beta-methoxy-19-norpregna-1,3,5(10),20-tetraene-3,17-diol (17 alpha-(iodovinyl)estradiol derivatives) as high specific activity potential radiopharmaceuticals. J Med Chem 1984 0.75
120 The status of radiopharmaceutical research. Int J Rad Appl Instrum B 1991 0.75
121 Binding characteristics and biological activity of 17 alpha-[125I]iodovinyl-11 beta-methoxyestradiol, an estrogen receptor-binding radiopharmaceutical, in human breast cancer cells (MCF-7). Cancer Res 1986 0.75
122 Boronic acid adducts of technetium dioxime (BATO) complexes derived from quinuclidine benzilate (QNB) boronic acid stereoisomers: syntheses and studies of their binding to the muscarinic acetylcholine receptor. Nucl Med Biol 1995 0.75
123 Vascular imaging with 99m Tc-red blood cells. Radiology 1973 0.75
124 Evaluation of beta adrenoceptor antagonist affinity and cardioselectivity by radioligand-receptor assay. J Pharmacol Exp Ther 1979 0.75
125 Radioiodinated derivatives of beta adrenoceptor blockers for myocardial imaging. J Nucl Med 1978 0.75
126 New compounds: fatty acid and long chain hydrocarbon derivatives containing a strong chelating agent. J Pharm Sci 1975 0.75
127 Cardioselectivity of beta-adrenoceptor blocking agents. 2. Role of the amino group substituent. J Med Chem 1983 0.75
128 Interaction of iodinated quinuclidinyl benzilate enantiomers with M3 muscarinic receptors. Life Sci 1994 0.75
129 Contrast media and radiopharmaceutical agents: regulatory issues. Acad Radiol 1995 0.75
130 Radioiodinated estrogen derivatives. J Nucl Med 1980 0.75
131 The chemistry of technetium labeling of radiopharmaceuticals by electrolysis. J Nucl Med 1974 0.75
132 Synthesis of polymer-bound 6-mercuric carboxylate DOPA precursors and solid phase labelling method of 6-radioiodinated L-DOPA. Appl Radiat Isot 1996 0.75
133 Direct analysis of whole blood by internal surface reversed-phase chromatography: an examination of the binding and metabolism of technetium dioxime complexes. J Chromatogr 1992 0.75
134 Receptor 1980 and Receptor 2000: twenty years of progress in receptor-binding radiotracers. Nucl Med Biol 2001 0.75
135 Agglutination of labeled RBC. J Nucl Med 1972 0.75
136 [125I]17-alpha-iodovinyl 11-beta-methoxyestradiol interaction in vivo with estrogen receptors in hormone-independent MCF-7 human breast cancer transfected with the v-rasH oncogene. Cancer Res 1987 0.75
137 A review of new oncotropic tracers for PET imaging. Nucl Med Biol 1996 0.75
138 Letter: Chemical state of technetium in vivo. J Nucl Med 1976 0.75
139 An automated radiopharmaceutical dispenser. Appl Radiat Isot 1997 0.75
140 Synthesis and evaluation of radioiodinated 6-iodo-L-DOPA as a cerebral L-amino acid transport marker. Nucl Med Biol 1996 0.75
141 Device-dependent activity estimation and decay correction of radionuclide mixtures with application to Tc-94m PET studies. Med Phys 2001 0.75
142 Analytical pitfalls with 99m Tc-labeled compounds. J Nucl Med 1972 0.75
143 Molecular modeling of the interaction of diagnostic radiopharmaceuticals with receptor proteins: m2 antagonist binding to the muscarinic m2 subtype receptor. Recept Signal Transduct 1997 0.75
144 Comparison of myocardial uptake and distribution of thallium-201 and two prototype receptor-binding radiopharmaceuticals in the normal and ischemic canine heart. Int J Nucl Med Biol 1984 0.75
145 Synthesis, characterization, and in vitro evaluation of nitroimidazole--BATO complexes: new technetium compounds designed for imaging hypoxic tissue. Bioconjug Chem 1994 0.75
146 Radiopharmaceutical quality assurance--pilot study. J Nucl Med 1981 0.75
147 99mTc-pyrophosphate for bone imaging. J Nucl Med 1974 0.75
148 The use of tritium labeled compounds to develop gamma-emitting receptor-binding radiotracers. Int J Nucl Med Biol 1982 0.75
149 99m Tc-DTPA preparations. J Nucl Med 1971 0.75
150 Re: Receptor binding of F-18 haloperidol and spiroperidol. J Nucl Med 1984 0.75
151 Nuclear imaging and biomarkers in drug development using approved radiopharmaceuticals. J Clin Pharmacol 2001 0.75
152 In vivo muscarinic binding selectivity of (R,S)- and (R,R)-[18F]-fluoromethyl QNB. Bioorg Med Chem 1997 0.75
153 Thyroidal pertechnetate uptake in Hashimoto's disease. Am J Roentgenol Radium Ther Nucl Med 1971 0.75
154 Calculation of binding isotherms when ligand and receptor are in different volumes of distribution. Anal Biochem 1980 0.75
155 In vivo competition studies with analogues of 3-quinuclidinyl benzilate. J Pharm Sci 1984 0.75
156 Synthesis of polymer-bound 6-thiolatomercury and 6-mercuric sulfonate DOPA precursors and their halodemercuration reactivity. Nucl Med Biol 1995 0.75
157 Electrophilic iodination of aromatic rings. Int J Nucl Med Biol 1984 0.75
158 Chemical and biologic properties of isolated radiolabeled bleomycin preparations. J Nucl Med 1975 0.75
159 Technical considerations in labeling of blood elements. Semin Nucl Med 1975 0.75
160 Synthesis and evaluation of radioiodinated derivatives of 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(4-iodophenyl)-alpha- phenylacetate as potential radiopharmaceuticals. J Med Chem 1984 0.75
161 Kinetic analysis of muscarinic receptors in human brain and salivary gland in vivo. Am J Physiol 1995 0.75
162 Autoradiographic evidence that (R)-3-quinuclidinyl (S)-4-fluoromethylbenzilate ((R,S)-FMeQNB) displays in vivo selectivity for the muscarinic m2 subtype. Nucl Med Biol 1996 0.75
163 Use of 3-quinuclidinyl 4-iodobenzilate as a receptor binding radiotracer. J Nucl Med 1985 0.75
164 Technetium-labeled red blood cells. J Nucl Med 1971 0.75
165 In vitro and in vivo characteristics of [iodine-125] 3-(R)-quinuclidinyl (S)-4-iodobenzilate. J Nucl Med 1989 0.75
166 Technetium labeling of albumin. J Nucl Med 1972 0.75